Freshfields Steers UCB's $680M Sale Of Chinese Portfolio
By Najiyya Budaly · August 27, 2024, 12:14 PM BST
UCB has said it will sell a portfolio of established products in China to investment firms in Singapore and Abu Dhabi for $680 million so that the Belgian biopharmaceutical company can focus...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login